Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 3

Status

Completed 5Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × bintrafusp alfa protein, human × Clear all
NCT04349280 2024-04-18

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

GlaxoSmithKline

Phase 1 Terminated
25 enrolled 10 charts
Tumor-Agnostic

Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
38 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡